Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).

Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F

Calcified tissue international13 Oct 2009Cited by 79 (Europe PMC)

PMID19823760PMCIDPMC2788127DOI10.1007/s00223-009-9299-6PepBankPUB-19823760

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
During teriparatide treatment, women with osteoporosis sustained 168 clinical fractures in 138 women (8.8%).
In plain wordsWomen treated with teriparatide sustained 168 clinical fractures in 138 women.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableClinical fractures
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Incident clinical fractures
168 fractures
18 months
Women with a clinical fracture
138 women
18 months
Women with a clinical fracture
8.8%
18 months
Fracture rate
821 fractures/10,000 patient-years
18 months
Source sentences
Summary
A total of 168 incident clinical fractures were sustained by 138 (8.8%) women (821 fractures/10,000 patient-years).
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376001
02HumanObservational studyEfficacy outcome
In women treated with teriparatide, fracture odds were 47% lower in the last than first 6-month period.
In plain wordsTeriparatide treatment was linked to lower fracture odds in the last versus first treatment period.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFracture odds over time
Study
n: not reported in source
Comparator
First 6-month period
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Decrease in odds of fracture
47%
last vs first 6-month period
Source sentences
Summary
A 47% decrease in the odds of fracture in the last 6-month period compared to the first 6-month period was observed (P < 0.005).
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376002
03HumanObservational studyEfficacy outcome
In women treated with teriparatide, mean back pain VAS decreased by 25.8 mm at endpoint.
In plain wordsTeriparatide treatment was linked to less back pain than at baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain VAS
Study
n: not reported in source
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Back pain VAS reduction
25.8 mm
end point vs baseline
Source sentences
Summary
Mean back pain VAS was reduced by 25.8 mm at end point (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376003
04HumanObservational studyEfficacy outcome
In women treated with teriparatide, EQ-VAS increased by 13 mm from baseline by 18 months.
In plain wordsTeriparatide treatment was linked to better health ratings than at baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEQ-VAS
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
EQ-VAS change from baseline
13 mm
by 18 months
Source sentences
Summary
Mean change from baseline in EQ-VAS was 13 mm by 18 months.
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376004
05HumanObservational studyEfficacy outcome
In women treated with teriparatide, the largest EQ-5D improvements were in the usual activities and pain/discomfort subdomains.
In plain wordsTeriparatide treatment was linked to improved usual activities and improved pain or discomfort, the largest quality-of-life improvements.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEQ-5D usual activities and pain/discomfort subdomains
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Source sentences
Summary
The largest improvements were reported in the EQ-5D subdomains of usual activities and pain/discomfort.
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376005
06HumanObservational studySafety outcome
Women treated with teriparatide reported 365 adverse events, with 48.0% considered treatment-related.
In plain wordsWomen treated with teriparatide reported 365 adverse events, with 48.0% considered related to treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSpontaneously reported adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Spontaneously reported adverse events
365 events
18 months
Events considered related to teriparatide
48%
18 months
Source sentences
Summary
There were 365 adverse events spontaneously reported, of which 48.0% were considered related to teriparatide;
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376006
07HumanObservational studySafety outcome
During teriparatide treatment, adverse events caused discontinuation in 79 patients (5.8%).
In plain wordsAdverse events caused 79 patients to stop teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableDiscontinuation for adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 18 monthsAs given in this study (human).
Measurements
Discontinuation due to adverse events
79 patients
18 months
Discontinuation due to adverse events
5.8%
18 months
Source sentences
Summary
adverse events were the reason for discontinuation for 79 (5.8%) patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The European Forsteo Observational Study was designed to examine the effectiveness of teriparatide in postmenopausal women with osteoporosis treated for up to 18 months in normal clinical practice in eight European countries.
Report a problemFND-1982376007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.